Montelair (Montelukast)

Montelukast, the active ingredient in Montelair, is a Leukotriene receptor antagonist presented as an oral dosage form for Oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to control airway inflammation and bronchoconstriction. - Asthma: Provides maintenance therapy that reduces the frequency and severity of symptoms and exacerbations. - Allergic rhinitis: Alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: Prevents airway narrowing that occurs during or after physical activity.

Montelukast may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain: discomfort or cramping in the stomach region. - Cough: occasional dry or productive cough. - Nausea: feeling of queasiness, sometimes with mild vomiting.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or urticaria requiring medical attention. - Neuropsychiatric events: agitation, depression, anxiety or suicidal thoughts. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder presenting with systemic symptoms.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: Category B, generally considered safe but use only if clearly needed. - Breastfeeding: Drug passes into milk; monitor infant for possible effects. - Renal or hepatic impairment: Dose may require adjustment; consult prescriber. - Concomitant asthma exacerbations: Continue rescue inhalers and do not discontinue inhaled steroids. - Neuropsychiatric symptoms: Observe for mood changes, depression or suicidal ideation. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Montelukast can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: may decrease therapeutic effectiveness. - Ketoconazole: may increase drug levels, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilation effect; assess clinical response. - ACE inhibitors: rare reports of angioedema; observe for swelling.